Ivonescimab for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Jun 2025: Trial started, NCT07070479
  2. 17 Jul 2025: Trial registered, NCT07070479

The trials

NCT07070479: Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

State
Under way
Phase
Phase 2
People
208 planned
Started
24 Jun 2025
Primary completion
30 Jan 2027
Arms
Ivonescimab Monotherapy
Results
None posted
  1. 24 Jun 2025: Trial started
  2. 17 Jul 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg, Ivonescimab Injection, Ivonescimab/surgery.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.